BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 30343636)

  • 1. An Assessment of Novel Biomarkers in Bone Metastatic Disease Using Multiplex Measurement and Multivariate Analysis.
    Windrichova J; Kucera R; Fuchsova R; Topolcan O; Fiala O; Svobodova J; Finek J; Slipkova D
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818807466. PubMed ID: 30343636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testing of a Novel Cancer Metastatic Multiplex Panel for the Detection of Bone-metastatic Disease - a Pilot Study.
    Windrichova J; Fuchsova R; Kucera R; Topolcan O; Fiala O; Finek J; Slipkova D; Karlikova M; Svobodova J
    Anticancer Res; 2016 Apr; 36(4):1973-8. PubMed ID: 27069189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MIC1/GDF15 as a Bone Metastatic Disease Biomarker.
    Windrichova J; Fuchsova R; Kucera R; Topolcan O; Fiala O; Finek J; Slipkova D
    Anticancer Res; 2017 Mar; 37(3):1501-1505. PubMed ID: 28314325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases.
    Wakabayashi H; Nakajima K; Mizokami A; Namiki M; Inaki A; Taki J; Kinuya S
    Ann Nucl Med; 2013 Nov; 27(9):802-7. PubMed ID: 23828554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases.
    Selander KS; Brown DA; Sequeiros GB; Hunter M; Desmond R; Parpala T; Risteli J; Breit SN; Jukkola-Vuorinen A
    Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):532-7. PubMed ID: 17372249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer?
    Bombardieri E; Martinetti A; Miceli R; Mariani L; Castellani MR; Seregni E
    Eur J Nucl Med; 1997 Nov; 24(11):1349-55. PubMed ID: 9371866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
    Ebert W; Muley T; Herb KP; Schmidt-Gayk H
    Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigations on bone metabolism of urological tumors forming metastases.
    Bichler KH; Petri E; Hub A; Kleinknecht S; Heidenreich A
    Urol Int; 1996; 56(2):61-8. PubMed ID: 8659012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone turnover markers and novel biomarkers in lung cancer bone metastases.
    Lang J; Zhao Q; He Y; Yu X
    Biomarkers; 2018 Sep; 23(6):518-526. PubMed ID: 29683727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Serum concentration of pyridinoline cross-linked carboxy-terminal telopeptide of type-I collagen (ICTP) and carboxyterminal propeptide of human type I procollagen (PICP) in the diagnosis of bone metastases].
    Koizumi M; Yamada Y; Takiguchi T; Suzuki C; Akashi T; Nomura E; Yamashita T; Ogata E
    Kaku Igaku; 1996 Jan; 33(1):77-84. PubMed ID: 8819718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
    Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
    Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer.
    Koizumi M; Yonese J; Fukui I; Ogata E
    J Urol; 2002 Apr; 167(4):1863-6. PubMed ID: 11912449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis.
    Tsai SH; Chen CY; Ku CH; Janckila AJ; Yam LT; Yu JC; Chuang KW; Chao TY
    Mayo Clin Proc; 2007 Aug; 82(8):917-26. PubMed ID: 17673059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications.
    Jung K; Lein M; Stephan C; Von Hösslin K; Semjonow A; Sinha P; Loening SA; Schnorr D
    Int J Cancer; 2004 Sep; 111(5):783-91. PubMed ID: 15252851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
    Wei RJ; Li TY; Yang XC; Jia N; Yang XL; Song HB
    Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between bone scintigraphy and serum levels of procollagen (I) and PSA in the detection of bone disease in prostate cancer patients.
    Zissimopoulos A; Bantis A; Stellos K; Petrakis G; Matthaios D
    J BUON; 2008; 13(1):69-74. PubMed ID: 18404790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases.
    Kasoha M; Unger C; Solomayer EF; Bohle RM; Zaharia C; Khreich F; Wagenpfeil S; Juhasz-Böss I
    Clin Exp Metastasis; 2017 Dec; 34(8):479-490. PubMed ID: 29426963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
    Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum procollagen 1 amino-terminal propeptide (P1NP) in prostate cancer: pitfalls of its use as an early surrogate marker for bone metastasis.
    Moseshvili E; Joseph DJ; Spry NA; Cohen RJ; Abreu A; Kautto A; Denham JW
    J Med Imaging Radiat Oncol; 2014 Aug; 58(4):497-502. PubMed ID: 24418365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A comparaison between the total PSA, the Gleason score and the bone scintiscan results for different age groups].
    Rusu D; Rusu V; Stefănescu C; Rusu M; Răileanu I; Stătescu AM
    Rev Med Chir Soc Med Nat Iasi; 2010; 114(2):476-83. PubMed ID: 20700990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.